Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.23
+0.22 (0.92%)
At close: Sep 2, 2025, 4:00 PM
24.21
-0.02 (-0.08%)
After-hours: Sep 2, 2025, 4:40 PM EDT
Castle Biosciences Revenue
Castle Biosciences had revenue of $86.19M in the quarter ending June 30, 2025, a decrease of -0.94%. This brings the company's revenue in the last twelve months to $346.27M, up 20.40% year-over-year. In the year 2024, Castle Biosciences had annual revenue of $332.07M with 51.09% growth.
Revenue (ttm)
$346.27M
Revenue Growth
+20.40%
P/S Ratio
1.97
Revenue / Employee
$455,018
Employees
761
Market Cap
702.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CSTL News
- 7 hours ago - Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential - Seeking Alpha
- 8 days ago - New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma - GlobeNewsWire
- 12 days ago - Castle Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Castle Biosciences Reports Second Quarter 2025 Results - GlobeNewsWire
- 5 weeks ago - Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 5 weeks ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal - GlobeNewsWire
- 5 weeks ago - FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test - GlobeNewsWire